Chronic Patellar TendinopathyNCT07819968
Chronic Patellar Tendinopathy (PT)is Prevalent in Participants of Several Sports.A Three-arm, Single-blind Randomized Controlled Trial Will be Conducted. We Want to Compare the Clinical Effectiveness of ESWT Alone, ESWT Combined With Hyaluronic Acid, and ESWT Combined With PRP in Athletes With PT
A study testing Extracorporeal Shock Wave Therapy, Hyaluronic Acid (HA) and Platelet-Rich Plasma in people with Chronic Patellar Tendinopathy, run by Chang Gung Memorial Hospital at 1 site in Taiwan.
Trial summary
Chronic patellar tendinopathy is highly prevalent among youth, amateur, and elite athletes, with rates reaching 30-40% in high-performance populations. Among current conservative treatments, platelet-rich plasma (PRP) injections and extracorporeal shockwave therapy (ESWT) have demonstrated promising clinical outcomes. Read more about this study
- Who is it for?
- Ages 15 to 40 years
- Conditions the study is for
- Chronic Patellar Tendinopathy
- What is being tested?
- Extracorporeal Shock Wave Therapy, Hyaluronic Acid (HA) and Platelet-Rich Plasma
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 45 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Sep 2026to 31 Jul 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 40 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Typical anterior knee pain ≥3 months (chronic stage) Pain location is concentrated at the lower or upper end of the patellar tendon Pain is aggravated by jumping, changing direction, sprinting, squat jumps, or weight-bearing knee extension movements
- Typical positive results on physical examination (at least two of the following must be positive):
- Positive Decline squat test Single-leg decline squat pain ≥3/10 Palpation tenderness over patellar tendon (tenderness ≥3/10) Pain induced by Hop test / drop jump
- Ultrasound imaging meets the criteria for chronic patellar tendinitis (at least two of the following imaging features must be present):
- Patellar tendon thickness >4.0 mm or thicker than the healthy side by ≥15% Hypoechoic area Disorganized fibers Doppler grade 1-2 neovascularity (5) Able to cooperate with research tracking and functional testing
Who cannot join
- Calcified tendinopathy
- Acute patellar tendon rupture, partial rupture, or post-operative condition
- Received other injectable treatments or high-energy laser/shockwave therapy within the past six months
- Systemic diseases including: autoimmune diseases (e.g., RA, AS), neuromuscular diseases, poorly controlled diabetes (HbA1c > 8.5%), blood disorders or currently using anticoagulants (unable to safely receive PRP or injections), infectious diseases
Trial locations and contacts
1 site in 1 country.
Taiwan1 site
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Kaohsiung, 833401
About this study
Official title: Comparative Effectiveness of Extracorporeal Shockwave Therapy Combined With Different Injection Treatments in Athletes With Chronic Patellar Tendinopathy: A Randomized Controlled Trial
Chronic patellar tendinopathy is highly prevalent among youth, amateur, and elite athletes, with rates reaching 30-40% in high-performance populations. Among current conservative treatments, platelet-rich plasma (PRP) injections and extracorporeal shockwave therapy (ESWT) have demonstrated promising clinical outcomes. However, high-quality randomized controlled trials comparing ESWT alone versus ESWT combined with different injection therapies remain lacking.
Objective:
Read more
To compare the clinical effectiveness of ESWT alone, ESWT combined with hyaluronic acid (HA), and ESWT combined with PRP in athletes with chronic patellar tendinopathy.
Methods:
A three-arm, single-blind randomized controlled trial will be conducted. Athletes participating in sports with repetitive jumping or explosive lower-limb loading will be enrolled and stratified by sport type. Inclusion criteria include typical anterior knee pain, a positive decline squat test, and ultrasonographic evidence of tendon thickening or hypoechoic changes. Calcified tendinopathy will be excluded.
Outcomes will be assessed at 1, 3, 6, 9, and 12 months, including VAS, VISA-P, SPORTS scale, sport-specific performance tests (vertical jump, single-leg hop, agility tests), and return-to-play (RTP) time.
Expected Impact:
This study aims to address three key clinical questions:
- Is ESWT alone adequate as an initial treatment for chronic patellar tendinopathy in athletes?
- If adjunctive injection is needed, does HA or PRP provide superior short- and long-term outcomes?
- Which treatment strategy results in the fastest safe return to sport? The findings of this trial will provide evidence-based guidance for clinicians and contribute to the development of more precise treatment algorithms, ultimately enhancing performance longevity and protecting the careers of high-level athletes.
Read the detailed description
- Research Objective: Chronic patellar tendinitis is a common and highly recurrent sports injury among advanced athletes. Currently, various non-surgical treatments, such as ESWT and PRP injections, are commonly used clinically. However, high-quality randomized controlled trials are lacking regarding whether combined injection therapy is necessary and whether ESWT combined with HA or PRP is more suitable for athletes. This study aims to comprehensively compare the efficacy of ESWT alone versus ESWT combined with either injection therapy through three parallel, stratified, randomized, single-blind clinical trials, providing clinically applicable treatment guidelines.
The objectives of this study are:
- To compare the clinical efficacy differences between ESWT alone and ESWT combined with HA/PRP.
- To compare the efficacy differences between ESWT combined with HA and ESWT combined with PRP at different time points.
- To clarify the impact of different treatment strategies on athletes' return to play (RTP).
- Research Hypotheses:
- ESWT combined with either HA or PRP will be superior to ESWT alone in terms of pain relief (VAS).
- ESWT combined with HA will be more effective than ESWT combined with PRP in short-term pain relief. (3) ESWT combined with PRP is superior to ESWT alone or ESWT+HA in terms of mid- to long-term functional improvement, motor performance, and specific tests.
- Study Endpoints
- Primary: Pain improvement at 3 months post-treatment (VAS change from baseline to 3 months)
- Secondary: Clinical Symptoms and Function Scales: VAS, VISA-P, SPORTS scale Return to Play (RTP): RTP duration (days), RTP level (complete, playable, with load limitations), relapse rate (12 months)
- Ultrasound indicators: thickness and elasticity, size of hypoechoic area, Doppler (neovascularity)
- Study Design
This study is a prospective clinical trial with three parallel, stratified, randomized, single-blind (subject-blind) groups. The study aimed to compare the clinical efficacy, functional recovery, and return to play (RTP) differences between:
- ESWT alone (ESWT + Placebo injection, microdose normal saline)
- ESWT combined with hyaluronic acid injection (ESWT+HA)
- ESWT combined with high-concentration platelet-plasma injection (ESWT+PRP) in athletes with chronic patellar tendinitis. The study procedure employed a standardized intervention protocol, uniform ultrasound diagnosis and injection site, and fixed ESWT energy settings. All follow-up tests and questionnaire completion were conducted by independent assessors unaware of their assigned groups.
- Conditions
- Chronic Patellar Tendinopathy
- Being tested
- Extracorporeal Shock Wave Therapy, Hyaluronic Acid (HA), Platelet-Rich Plasma, Normal Saline
- Keywords
- Extracorporeal shockwave therapy, Hyaluronic acid, Platelet-rich plasma, Sports medicine, Chronic Patellar Tendinopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Extracorporeal Shock Wave TherapyDevice
Shockwave therapy is a treatment method that uses high-energy sound waves delivered to body tissues.
Through shockwave stimulation of specific frequencies and energy levels, it acts on areas of pain or dysfunction, promoting tissue repair. It is commonly used for chronic musculoskeletal discomfort and sports injury-related problems.
In this program, shockwave therapy is the basic treatment, and each experimental group will receiveExtracorporeal Shock Wave Therapy (
Hyaluronic Acid (HA)Drug
Hyaluronic acid is primarily used in medicine as an intra-articular injection to relieve pain from osteoarthritis and lubricate joints.
Platelet-Rich PlasmaBiological
PRP (Platelet-Rich Plasma) Brief Introduction and Definition: Concentrated blood plasma rich in platelets and growth factors, extracted from the patient's own blood. Uses: Belonging to regenerative medicine and proliferative therapy, it is commonly used to help repair soft tissues such as muscles, tendons, ligaments, and joints. Principle: Utilizing growth factors from the patient's own blood, it accelerates the healing and regeneration of body tissues.
Normal SalineOther
Normal saline is a 0.9% sterile aqueous solution of sodium chloride. Its osmotic pressure is similar to that of human blood plasma, and it is widely used in medical and daily care. In this study, it was used as a placebo.
| Study group | Role | What they receive |
|---|---|---|
| ESWT+normal saline | Placebo comparator | This group served as the control group in the experimental design, receiving only shockwave therapy. Saline was administered only for the purpose of a single-blind trial. Receives: Device: Extracorporeal Shock Wave Therapy; Other: Normal Saline |
| ESWT+hyaluronic acid (HA) | Active comparator | deliver a gel-like fluid directly into the joint to lubricate cartilage and relieve osteoarthritis pain when basic treatments fail.
Hyaluronic acid combined with shockwave therapy aims to achieve effects beyond pain relief. Receives: Device: Extracorporeal Shock Wave Therapy; Drug: Hyaluronic Acid (HA) |
| ESWT+Pplatelet-rich plasma (PRP) | Active comparator | A platelet-rich plasma (PRP) injection is a treatment that uses a high concentration of your own blood platelets to help heal injured joints, tendons, and muscles.
The combination of PRP and shockwave therapy is expected to achieve results exceeding those of either treatment alone. Receives: Device: Extracorporeal Shock Wave Therapy; Biological: Platelet-Rich Plasma |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual Analogue Scale(VAS)
VAS（Visual Analogue Scale）：Ask the patient to mark the degree of their pain on a 10 cm line, from "no pain" on the far left to "unbearable pain" on the far right. The "Numerical Rating Scale" uses a numerical concept of 0-10 points to express the degree of pain, from no pain (0 points) to very painful (10 points).
Measured: From enrollment to the end of treatment at 48 weeks
Secondary outcomes (3)
The Victorian Institute of Sport Assessment (VISA-) Patella (P) Questionnaire
VISA-P: A professional self-assessment tool used to evaluate the severity and treatment effectiveness of patellar tendinopathy.
The maximum score is 100 points. A higher score indicates milder symptoms and better function; a lower score indicates a more severe condition. Question Structure: Contains 8 questions.
First 6 questions: Assess the degree of pain and functional limitations in specific daily activities (such as sitting, squatting, climbing stairs, hopping on one leg, etc.).
Last 2 questions: Assess the level of motor engagement, the ability to train, and the duration of training.
Measured: From enrollment to the end of treatment at 48 weeks
SPORTS score (Subjective Patient Outcome for Return to Sports)
In the fields of sports medicine and orthopedics, the SPORTS scale (Subjective Patient Outcome for Return to Sports score) is a core assessment scale specifically designed to evaluate an athlete's ability to return to sports (RTS) after experiencing a sports injury (such as anterior cruciate ligament rupture, shoulder instability, elbow injury, etc.) and undergoing surgery or treatment.
It comprises three independent conceptual constructs: 1) the ability to return to pre-injury intensity and training levels; 2) the ability to achieve the same level of athletic performance; and 3) the ability to achieve 1) and 2 above without pain or with pain relief. This tool uses a 10-point scale, where 0 indicates the patient cannot return to their pre-injury level of athletic performance, and 10 indicates the patient can perform the same sport with the same effort and performance level as before the injury without pain
Measured: From enrollment to the end of treatment at 48 weeks
Return to Play (RTP)
Return to Play (RTP) refers to the complete decision-making process by which athletes safely and gradually return to training and competition after injury or surgery, through medical treatment, physical therapy, and scientific training.
RTP comprises three main phases:
Return to Participation: Begin non-contact, basic physical and technical rehabilitation training.
Return to Sport: Participate in sport-specific movements, simulated competition, and team training.
Return to Performance: Recover to the pre-injury competitive level and peak performance.
Measured: From enrollment to the end of treatment at 48 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2026
- Study start1 Sep 2026
- Primary completion31 Jul 2027 (estimated)
- Study completion31 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Patellar TendinopathyStudies of the same condition, open and under way.
- More trials run by Chang Gung Memorial HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A three-arm, single-blind randomized controlled trial will be conducted. 1. Extracorporeal shockwave therapy (ESWT)+saline injection 2. Extracorporeal shockwave therapy (ESWT)+HA injection 3. Extracorporeal shockwave therapy (ESWT)+PRP
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chang Gung Memorial Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07819968
- Sponsor's protocol ID
- 202501717A3C5001
- Other IDs
- NMRPG8R0191
- Status last verified
- Sep 2026
- First submitted
- 3 Sep 2026
- Last updated
- 15 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Effectiveness of Extracorporeal Shockwave Therapy Combined With Different Injection Treatments in Athletes With Chronic Patellar Tendinopathy: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07819968
- Acronym / sponsor ID
- 202501717A3C5001
- Conditions
- Chronic Patellar Tendinopathy
- Keywords
- Extracorporeal shockwave therapy, Hyaluronic acid, Platelet-rich plasma, Sports medicine, Chronic Patellar Tendinopathy
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- Chang Gung Memorial HospitalUniversity, hospital or other
- Study start
- 1 Sep 2026 (actual)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Jul 2028 (estimated)
- First posted
- 15 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic patellar tendinopathy is highly prevalent among youth, amateur, and elite athletes, with rates reaching 30-40% in high-performance populations. Among current conservative treatments, platelet-rich plasma (PRP) injections and extracorporeal shockwave therapy (ESWT) have demonstrated promising clinical outcomes. However, high-quality randomized controlled trials comparing ESWT alone versus ESWT combined with different injection therapies remain lacking.
Objective:
To compare the clinical effectiveness of ESWT alone, ESWT combined with hyaluronic acid (HA), and ESWT combined with PRP in athletes with chronic patellar tendinopathy.
Methods:
A three-arm, single-blind randomized controlled trial will be conducted. Athletes participating in sports with repetitive jumping or explosive lower-limb loading will be enrolled and stratified by sport type. Inclusion criteria include typical anterior knee pain, a positive decline squat test, and ultrasonographic evidence of tendon thickening or hypoechoic changes. Calcified tendinopathy will be excluded.
Outcomes will be assessed at 1, 3, 6, 9, and 12 months, including VAS, VISA-P, SPORTS scale, sport-specific performance tests (vertical jump, single-leg hop, agility tests), and return-to-play (RTP) time.
Expected Impact:
This study aims to address three key clinical questions:
- Is ESWT alone adequate as an initial treatment for chronic patellar tendinopathy in athletes?
- If adjunctive injection is needed, does HA or PRP provide superior short- and long-term outcomes?
- Which treatment strategy results in the fastest safe return to sport? The findings of this trial will provide evidence-based guidance for clinicians and contribute to the development of more precise treatment algorithms, ultimately enhancing performance longevity and protecting the careers of high-level athletes.
Detailed description
- Research Objective: Chronic patellar tendinitis is a common and highly recurrent sports injury among advanced athletes. Currently, various non-surgical treatments, such as ESWT and PRP injections, are commonly used clinically. However, high-quality randomized controlled trials are lacking regarding whether combined injection therapy is necessary and whether ESWT combined with HA or PRP is more suitable for athletes. This study aims to comprehensively compare the efficacy of ESWT alone versus ESWT combined with either injection therapy through three parallel, stratified, randomized, single-blind clinical trials, providing clinically applicable treatment guidelines.
The objectives of this study are:
- To compare the clinical efficacy differences between ESWT alone and ESWT combined with HA/PRP.
- To compare the efficacy differences between ESWT combined with HA and ESWT combined with PRP at different time points.
- To clarify the impact of different treatment strategies on athletes' return to play (RTP).
- Research Hypotheses:
- ESWT combined with either HA or PRP will be superior to ESWT alone in terms of pain relief (VAS).
- ESWT combined with HA will be more effective than ESWT combined with PRP in short-term pain relief. (3) ESWT combined with PRP is superior to ESWT alone or ESWT+HA in terms of mid- to long-term functional improvement, motor performance, and specific tests.
- Study Endpoints
- Primary: Pain improvement at 3 months post-treatment (VAS change from baseline to 3 months)
- Secondary: Clinical Symptoms and Function Scales: VAS, VISA-P, SPORTS scale Return to Play (RTP): RTP duration (days), RTP level (complete, playable, with load limitations), relapse rate (12 months)
- Ultrasound indicators: thickness and elasticity, size of hypoechoic area, Doppler (neovascularity)
- Study Design
This study is a prospective clinical trial with three parallel, stratified, randomized, single-blind (subject-blind) groups. The study aimed to compare the clinical efficacy, functional recovery, and return to play (RTP) differences between:
- ESWT alone (ESWT + Placebo injection, microdose normal saline)
- ESWT combined with hyaluronic acid injection (ESWT+HA)
- ESWT combined with high-concentration platelet-plasma injection (ESWT+PRP) in athletes with chronic patellar tendinitis. The study procedure employed a standardized intervention protocol, uniform ultrasound diagnosis and injection site, and fixed ESWT energy settings. All follow-up tests and questionnaire completion were conducted by independent assessors unaware of their assigned groups.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
- Model description
- A three-arm, single-blind randomized controlled trial will be conducted. 1. Extracorporeal shockwave therapy (ESWT)+saline injection 2. Extracorporeal shockwave therapy (ESWT)+HA injection 3. Extracorporeal shockwave therapy (ESWT)+PRP
| Arm | Type | Receives |
|---|---|---|
| ESWT+normal saline | Placebo comparator | Device: Extracorporeal Shock Wave Therapy, Other: Normal SalineThis group served as the control group in the experimental design, receiving only shockwave therapy. Saline was administered only for the purpose of a single-blind trial. |
| ESWT+hyaluronic acid (HA) | Active comparator | Device: Extracorporeal Shock Wave Therapy, Drug: Hyaluronic Acid (HA)deliver a gel-like fluid directly into the joint to lubricate cartilage and relieve osteoarthritis pain when basic treatments fail. Hyaluronic acid combined with shockwave therapy aims to achieve effects beyond pain relief. |
| ESWT+Pplatelet-rich plasma (PRP) | Active comparator | Device: Extracorporeal Shock Wave Therapy, Biological: Platelet-Rich PlasmaA platelet-rich plasma (PRP) injection is a treatment that uses a high concentration of your own blood platelets to help heal injured joints, tendons, and muscles. The combination of PRP and shockwave therapy is expected to achieve results exceeding those of either treatment alone. |
Who may qualify
- Ages
- 15 to 40 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (5 listed)
- Typical anterior knee pain ≥3 months (chronic stage) Pain location is concentrated at the lower or upper end of the patellar tendon Pain is aggravated by jumping, changing direction, sprinting, squat jumps, or weight-bearing knee extension movements
- Typical positive results on physical examination (at least two of the following must be positive):
- Positive Decline squat test Single-leg decline squat pain ≥3/10 Palpation tenderness over patellar tendon (tenderness ≥3/10) Pain induced by Hop test / drop jump
- Ultrasound imaging meets the criteria for chronic patellar tendinitis (at least two of the following imaging features must be present):
- Patellar tendon thickness >4.0 mm or thicker than the healthy side by ≥15% Hypoechoic area Disorganized fibers Doppler grade 1-2 neovascularity (5) Able to cooperate with research tracking and functional testing
Key exclusion criteria (4 listed)
- Calcified tendinopathy
- Acute patellar tendon rupture, partial rupture, or post-operative condition
- Received other injectable treatments or high-energy laser/shockwave therapy within the past six months
- Systemic diseases including: autoimmune diseases (e.g., RA, AS), neuromuscular diseases, poorly controlled diabetes (HbA1c > 8.5%), blood disorders or currently using anticoagulants (unable to safely receive PRP or injections), infectious diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Extracorporeal Shock Wave TherapyShockwave therapy is a treatment method that uses high-energy sound waves delivered to body tissues. Through shockwave stimulation of specific frequencies and energy levels, it acts on areas of pain or dysfunction, promoting tissue repair. It is commonly used for chronic musculoskeletal discomfort and sports injury-related problems. In this program, shockwave therapy is the basic treatment, and each experimental group will receiveExtracorporeal Shock Wave Therapy ( | Device | ESWT+Pplatelet-rich plasma (PRP), ESWT+hyaluronic acid (HA), ESWT+normal saline |
| Hyaluronic Acid (HA)Hyaluronic acid is primarily used in medicine as an intra-articular injection to relieve pain from osteoarthritis and lubricate joints. | Drug | ESWT+hyaluronic acid (HA) |
| Platelet-Rich PlasmaPRP (Platelet-Rich Plasma) Brief Introduction and Definition: Concentrated blood plasma rich in platelets and growth factors, extracted from the patient's own blood. Uses: Belonging to regenerative medicine and proliferative therapy, it is commonly used to help repair soft tissues such as muscles, tendons, ligaments, and joints. Principle: Utilizing growth factors from the patient's own blood, it accelerates the healing and regeneration of body tissues. | Biological | ESWT+Pplatelet-rich plasma (PRP) |
| Normal SalineNormal saline is a 0.9% sterile aqueous solution of sodium chloride. Its osmotic pressure is similar to that of human blood plasma, and it is widely used in medical and daily care. In this study, it was used as a placebo. | Other | ESWT+normal saline |
Primary outcome
Visual Analogue Scale(VAS)
Time frame: From enrollment to the end of treatment at 48 weeks
VAS（Visual Analogue Scale）：Ask the patient to mark the degree of their pain on a 10 cm line, from "no pain" on the far left to "unbearable pain" on the far right. The "Numerical Rating Scale" uses a numerical concept of 0-10 points to express the degree of pain, from no pain (0 points) to very painful (10 points).
3 secondary outcomes
The Victorian Institute of Sport Assessment (VISA-) Patella (P) Questionnaire
Time frame: From enrollment to the end of treatment at 48 weeks
SPORTS score (Subjective Patient Outcome for Return to Sports)
Time frame: From enrollment to the end of treatment at 48 weeks
Return to Play (RTP)
Time frame: From enrollment to the end of treatment at 48 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2026.
Related trials for Chronic Patellar Tendinopathy
Enrolling by invitation
Effects of Resistance Training on Patellar Tendon Properties in People With Patellar Tendinoapthy
Patellar Tendinopathy
RecruitingObservational study
Evaluation of Platelet-Rich Plasma (PRP) Treatment in Tendinopathies
Patellar Tendinopathy, Achilles Tendinopathy (AT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Extracorporeal Shock Wave Therapy, Hyaluronic Acid (HA) and Platelet-Rich Plasma in people with Chronic Patellar Tendinopathy, run by Chang Gung Memorial Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual Analogue Scale(VAS) (time frame: From enrollment to the end of treatment at 48 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026.